Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
OptimizeRx
OPRX
OptimizeRx
Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
15 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$11.00
56.8% overvalued
intrinsic discount
15 Aug
US$17.25
Loading
1Y
100.6%
7D
2.3%
Author's Valuation
US$11.0
56.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$11.0
56.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-18m
128m
2014
2017
2020
2023
2025
2026
2028
Revenue US$128.4m
Earnings US$11.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.47%
Healthtech revenue growth rate
4.07%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.03%
Calculation
US$11.26m
Earnings '28
x
23.41x
PE Ratio '28
=
US$263.44m
Market Cap '28
US$263.44m
Market Cap '28
/
19.31m
No. shares '28
=
US$13.64
Share Price '28
US$13.64
Share Price '28
Discounted to 2025 @ 8.02% p.a.
=
US$10.82
Fair Value '25
